Skip to main content
Premium Trial:

Request an Annual Quote

Biora Therapeutics Sells Cell-Free DNA Patents to Roche Diagnostics

NEW YORK – Biora Therapeutics, formerly known as Progenity, said on Thursday that it has sold certain patent rights related to determining the origin of cell-free DNA to Roche Diagnostics.

Financial and other terms of the deal were not disclosed. 

The patents are directed to methods and systems for determining the origin of DNA molecules in a cell-free bodily fluid sample, San Diego-based Biora said in a statement. The patent family, which resulted from Biora's previous molecular diagnostics research and development activities, includes an allowed application in Europe, a divisional application in Europe, and a pending application in the US. 

The applications describe the use of the technology to determine fetal fraction, detect the presence of cancer and transplant rejection, monitor organ failure or tissue necrosis, and diagnose heart disease, the firm said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.